The PI-RADS™ v2 system is an international collaboration between the American College of Radiology (ACR), European Society of Uroradiology (ESUR), and AdMeTech Foundation. It aims to standardize the interpretation and reporting of multiparametric magnetic resonance imaging (mpMRI) for prostate cancer, reducing variability in acquisition, interpretation, and reporting. It provides assessment categories to help select patients for biopsies and management, and is intended for routine clinical use and research. PI-RADS™ v2 is based on the best available evidence and expert consensus, and is designed to be a "living" document that evolves with new data. It is not a comprehensive diagnosis tool and should be used alongside other resources. PI-RADS™ v2 is intended to improve detection, localization, characterization, and risk stratification of clinically significant prostate cancer. It includes technical specifications for MRI, such as magnetic field strength, endorectal coil use, and computer-aided evaluation. It also includes normal anatomy and benign findings, and assessment and reporting guidelines. The system uses a 5-point scale to assess the likelihood of clinically significant cancer based on T2W, DWI, and DCE findings. It also includes caveats for overall assessment, such as the importance of consistent imaging plane angles and slice thickness, and the need to consider the zonal location of lesions. The system also includes technical specifications for T1W, T2W, DWI, and DCE imaging, and provides guidance on lesion measurement and reporting. It is intended to improve outcomes for patients by facilitating targeted biopsy and management.The PI-RADS™ v2 system is an international collaboration between the American College of Radiology (ACR), European Society of Uroradiology (ESUR), and AdMeTech Foundation. It aims to standardize the interpretation and reporting of multiparametric magnetic resonance imaging (mpMRI) for prostate cancer, reducing variability in acquisition, interpretation, and reporting. It provides assessment categories to help select patients for biopsies and management, and is intended for routine clinical use and research. PI-RADS™ v2 is based on the best available evidence and expert consensus, and is designed to be a "living" document that evolves with new data. It is not a comprehensive diagnosis tool and should be used alongside other resources. PI-RADS™ v2 is intended to improve detection, localization, characterization, and risk stratification of clinically significant prostate cancer. It includes technical specifications for MRI, such as magnetic field strength, endorectal coil use, and computer-aided evaluation. It also includes normal anatomy and benign findings, and assessment and reporting guidelines. The system uses a 5-point scale to assess the likelihood of clinically significant cancer based on T2W, DWI, and DCE findings. It also includes caveats for overall assessment, such as the importance of consistent imaging plane angles and slice thickness, and the need to consider the zonal location of lesions. The system also includes technical specifications for T1W, T2W, DWI, and DCE imaging, and provides guidance on lesion measurement and reporting. It is intended to improve outcomes for patients by facilitating targeted biopsy and management.